5-氨基-2-溴嘧啶 | 56621-91-1

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-氨基-2-溴嘧啶
• 中文别名: 2-溴-5-氨基嘧啶
• 英文名称: 2-bromopyrimidin-5-amine
• 英文别名: 5-amino-2-bromopyrimidine；5-Amino-2-brompyrimidin
• CAS: 56621-91-1
• 化学式: C₄H₄BrN₃
• 分子量: 174.0
• InChiKey: BTXWPEMYVHUOPW-UHFFFAOYSA-N

物化性质

• 熔点：
  182-183 °C(Solv: benzene (71-43-2))
• 沸点：
  364.1±34.0 °C(Predicted)
• 密度：
  1.844±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P301+P312+P330
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Amino-2-bromopyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Amino-2-bromopyrimidine
CAS number: 56621-91-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H4BrN3
Molecular weight: 174.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Boc-beta-丙氨酸 、 5-氨基-2-溴嘧啶 在 1-丙基磷酸酐 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以47%的产率得到tert-butyl 3-(2-bromopyrimidin-5-ylamino)-3-oxopropylcarbamate
  参考文献：
  名称：

  [EN] HETEROARYL-CARBOXAMIDES AS HISTONE DEMETHYLASE INHIBITORS
  [FR] HÉTÉROARYL-CARBOXAMIDES COMME INHIBITEURS DE L'HISTONE DÉMÉTHYLASE

  摘要：

  本发明涉及如本文所述的杂环基-羧酰胺，其作为组蛋白去甲基酶抑制剂具有用处。本发明还涉及包含这些化合物的药物组合物，以及它们在治疗中的应用，包括例如在癌症治疗中的应用。

  公开号：

  WO2018219478A1
• 作为产物：
  描述：

  (2-溴嘧啶-5-基)氨基酸叔丁酯 在 2,6-二甲基吡啶 、 1-methoxy-4-((4-(2-methoxyethyl)phenoxy)methyl)benzene 、 erbium(III) triflate 作用下， 以 四氢呋喃 为溶剂， 生成 5-氨基-2-溴嘧啶
  参考文献：
  名称：

  [EN] METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUPS
  [FR] PROCÉDÉ DE RETRAIT DE GROUPE TERT-BUTOXYCARBONYLE
  [JA] ｔｅｒｔ－ブトキシカルボニル基の除去方法

  摘要：

  本発明により、窒素原子上にtert-ブトキシカルボニル（Boc）基を有する化合物におけるBoc基の除去方法であって、該化合物を、トリフルオロメタンスルホン酸金属塩（金属トリフラート：M(OTf)n）または希土類金属ハロゲン化物（MXn）と塩基の存在下で処理し、Boc基をH-に変換した化合物を得ることを含む、前記方法が提供される。

  公开号：

  WO2023132353A1

文献信息

• Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor
  作者：Jonathan E. Wilson、Gaurav Patel、Chirag Patel、Francois Brucelle、Annissa Huhn、Anna S. Gardberg、Florence Poy、Nico Cantone、Archana Bommi-Reddy、Robert J. Sims、Richard T. Cummings、Julian R. Levell

  DOI：10.1021/acsmedchemlett.0c00155

  日期：2020.6.11

  inflammatory disorders, and neurodegeneration. A novel, highly potent, orally bioavailable EP300/CBP histone acetyltransferase (HAT) inhibitor, CPI-1612 or 17, was developed from the lead compound 3. Replacement of the indole scaffold of 3 with the aminopyridine scaffold of 17 led to improvements in potency, solubility, and bioavailability. These characteristics resulted in a 20-fold lower efficacious

  组蛋白乙酰基转移酶，CREB结合蛋白（CBP）和EP300是主要的转录共调节剂，与多种疾病有关，例如癌症，炎症性疾病和神经变性。从铅化合物3开发了一种新型的高效口服生物利用EP300 / CBP组蛋白乙酰转移酶（HAT）抑制剂CPI-1612或17。用17的氨基吡啶支架替换3的吲哚支架导致效力，溶解度和生物利用度的提高。在JEKO-1肿瘤小鼠异种移植研究中，这些特性导致17的有效剂量相对于铅3降低了20倍。
• [EN] SMALL MOLECULE MODULATORS OF IL-17<br/>[FR] MODULATEURS À PETITES MOLÉCULES D'IL-17
  申请人：LEO PHARMA AS

  公开号：WO2021250194A1

  公开（公告）日：2021-12-16

  The present invention relates to a compound according to formula (I), (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及一种符合式(I)的化合物，以及其药学上可接受的盐、水合物或溶剂合物。该发明还涉及上述化合物在治疗中的应用，包括包含该化合物的药物组合物，用于使用该化合物制造药物的方法，例如用于治疗皮肤病等疾病的方法。
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011084402A1

  公开（公告）日：2011-07-14

  The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及吡啶并嗪-4(1H)-酮衍生物，用于治疗细胞增殖性疾病，治疗与MET活性相关的疾病，并抑制受体酪氨酸激酶MET。该发明还涉及包含这些化合物的组合物，以及利用它们治疗哺乳动物癌症的方法。
• 稠环化合物、包含其的药物组合物及其制备方法和用途
  申请人：四川科伦博泰生物医药股份有限公司

  公开号：CN111285882B

  公开（公告）日：2022-12-02

  本发明涉及式(I‑A)或式(I‑B)的稠环化合物、包含其的药物组合物、其制备方法及其用于预防或治疗与RET活性相关的疾病或病况。
• New Non-Peptide Endothelin-A Receptor Antagonists:  Synthesis, Biological Properties, and Structure−Activity Relationships of 5-(Dimethylamino)-<i>N</i>-pyridyl-, -<i>N</i>-pyrimidinyl-, -<i>N</i>-pyridazinyl-, and -<i>N</i>-pyrazinyl-1-naphthalenesulfonamides
  作者：Robert H. Bradbury、Colin Bath、Roger J. Butlin、Michael Dennis、Christine Heys、Sarah J. Hunt、Roger James、Andrew A. Mortlock、Neil F. Sumner、Eric K. Tang、Berwick Telford、Elaine Whiting、Campbell Wilson

  DOI：10.1021/jm9604585

  日期：1997.3.1

  led to the discovery of several 6-membered nitrogen heterocycles as replacements for the N-isoxazolyl substituent present in the 1-naphthalenesulfonamides endothelin-A (ETA) antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesu lfo namides (BMS 182874). In each of these heterocycles, a small substituent such as halogen para to the position of attachment to the sulfonamide nitrogen

  自动合成的使用导致发现了几个6元氮杂环取代了1-萘磺酰胺类内皮素A（ETA）拮抗剂5-（二甲基氨基）-N-（3,4-二甲基）中存在的N-异恶唑基取代基-5-异恶唑基）-1-萘酰胺（BMS 182874）。在这些杂环的每一个中，发现小的取代基，例如在与磺酰胺氮原子的连接位置对位的卤素，对ETA受体亲和力是有利的。在这些杂环中，2-吡嗪提供了最大的改善受体亲和力的范围。在吡嗪环的3-和5-位上的取代基的优化导致有效的，ETA-选择性化合物，例如5-（二甲基氨基）-N-（5-氯-3-甲氧基-2-吡嗪基）-1-萘磺酰胺（7m，ETA pIC50 8.1）。当以10 mg / kg的剂量口服给清醒者时，